Taysha Gene Therapies Total Liabilities 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Taysha Gene Therapies Total Liabilities 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
Dr Reddy's Laboratories (RDY)	$11.2B
BridgeBio Pharma (BBIO)	$6.9B
Bausch Health Cos (BHC)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1.5B
Personalis (PSNL)	$412M
Assembly Biosciences (ASMB)	$81M
Sol-Gel Technologies (SLGL)	$16M
Evoke Pharma (EVOK)	$8M
Teligent (TLGT)	$0M